General Information of the Drug (ID: M6APDG04253)
Name
OT-101
Status
Phase 2/3
TTD Drug ID
DO5H6K
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Transforming growth factor beta 2 (TGFB2)
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
Response Summary Transforming growth factor beta 2 (TGFB2) is a therapeutic target for OT-101. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of OT-101 through regulating the expression of Transforming growth factor beta 2 (TGFB2). [1], [2]
References
Ref 1 Genetic variants in m6A modification genes are associated with esophageal squamous-cell carcinoma in the Chinese population. Carcinogenesis. 2020 Jul 10;41(6):761-768. doi: 10.1093/carcin/bgaa012.
Ref 2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210)